A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies ; volume:7 ; number:1 ; day:14 ; month:4 ; year:2014 ; pages:1-13 ; date:12.2014
Journal of hematology & oncology ; 7, Heft 1 (14.4.2014), 1-13, 12.2014
- Creator
-
Breton, Caroline S.
Nahimana, Aimable
Aubry, Dominique
Macoin, Julie
Moretti, Pierre
Bertschinger, Martin
Hou, Samuel
Duchosal, Michel A.
Back, Jonathan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1756-8722-7-33
- URN
-
urn:nbn:de:101:1-2019102706134912556922
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Breton, Caroline S.
- Nahimana, Aimable
- Aubry, Dominique
- Macoin, Julie
- Moretti, Pierre
- Bertschinger, Martin
- Hou, Samuel
- Duchosal, Michel A.
- Back, Jonathan
- SpringerLink (Online service)
Other Objects (12)
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
GBR.
GBR
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
GBR-Ausschuß
GBR-Ausschuß
BA/GBR
GBR-Ausschuß
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
GBR.
GBR
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
GBR-Ausschuß
GBR-Ausschuß
BA/GBR
GBR-Ausschuß
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
GBR.
GBR
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
GBR-Ausschuß
GBR-Ausschuß
BA/GBR